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Abstract
One of the most spectacular advances in the history of scientific knowledge was the discovery of
deoxyribonucleic acid (DNA) by Watson and Crick in 1953. This enabled certain proteins to be
prepared in this way for their therapeutic use in clinical practice. Today, in the first decade of the
21st century, hundreds of therapeutic proteins have been produced recombinantly and about 50
of them have been approved for clinical use. Because of the specific procedure used for obtaining
these products, which is based on expressing a atherapeutica gene from a fragment of DNA in a
cell to produce a functional protein that is free from any human or animal component, they are
especially acleana and thus the therapy of choice for many current diseases. The immediate
question is: why are recombinant products not used more extensively given their high efficacy and
maximum safety? In short, we are faced with an interesting but also unfortunate paradox of
pharmacology that greater progress in therapeutic procedures is not always associated with
greater introduction of those resources that are safest, for the simple reason that they are more
costly.
One of the most spectacular advances in the history of sci-
entific knowledge was the discovery of deoxyribonucleic
acid (DNA) by Watson and Crick in 1953 [1]. This discov-
ery made possible what is today known as "modern" bio-
technology, in which a fragment of DNA is inserted into a
bacterial or eukaryotic cell (animal or plant) to obtain a
specific protein – called recombinant – with a specific
function. This enabled certain proteins such as insulin,
growth hormone, or plasminogen activator to be prepared
using this procedure for therapeutic use in clinical prac-
tice. Today, in the first decade of the 21st century, hun-
dreds of therapeutic proteins have been produced using
recombinant technology, and approximately 50 of them
have been approved for clinical use.
However, before this therapeutic approach became a real-
ity, some dramatic iatrogenic consequences had to be
assumed, such as the occurrence many years ago of some
cases of Creutzfeldt-Jakob disease in children who were
treated with growth hormone obtained from post-mor-
tem human pituitary glands. Development of recom-
binant proteins was also marked by massive and fatal
infection with the human immunodeficiency virus (HIV),
the cause of AIDS, in the 1980s, and the hepatitis C virus
(HCV) in the 1990s.
Putting aside the past, that should be devoted no more
time than that required to give a cautionary warning, the
present and even more so the future lies in "recombinant
medicines". Because of the unique procedure used for
obtaining these products, which is based on expressing a
Published: 28 April 2008
International Archives of Medicine 2008, 1:4 doi:10.1186/1755-7682-1-4
Received: 23 January 2008
Accepted: 28 April 2008
This article is available from: http://www.intarchmed.com/content/1/1/4
© 2008 Liras; licensee BioMed Central Ltd. 
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), 
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.International Archives of Medicine 2008, 1:4 http://www.intarchmed.com/content/1/1/4
Page 2 of 4
(page number not for citation purposes)
"therapeutic" gene from a DNA fragment in a cell to pro-
duce a functional protein free from any human or animal
component, they are especially "clean", and are therefore
the treatment of choice for many current diseases. How-
ever, this simple idea, which is not still fully assimilated
by the more conservative physicians, was not established
in a systematic manner. The first recombinant proteins
used in clinical practice, such as somatostatin in 1976,
insulin in 1982, erythropoietin in 1986, interferon in
1986, tissue plasminogen activator in 1987, or coagula-
tion factors in 1990, raised a great skepticism because of
the fear of what were at the time – but not now – the enor-
mously unknown fields of molecular biology and genetic
engineering (Figure 1).
Despite this, a large number of biotechnology companies
were then created, which resulted in a new concept of
pharmaceutical company, the "biotechnology company",
and even traditional pharmaceutical companies were
reorganized to work in the field of genetic pharmacology.
At the same time, the Biotechnology Industry Organiza-
tion was founded to support the advancement of this sec-
tor. Investment continues to increase, and it is estimated
that these medicinal products will represent more than
25% of the world pharmaceutical market in the mid or
long term.
Many recombinant proteins are today part of standard
therapy, and some of them have been used in clinical
practice for more than 20 years with an optimal safety and
high efficacy and absence of side effects [2]. Others are
still in the preliminary study phase, such as those that may
be useful in Graves' disease, multiple sclerosis, myasthe-
nia gravis, scleroderma, phenylketonuria, galactosemia,
hemoglobinopathies, and other diseases (Table 1).
Recombinant vaccines used in the general population, but
also in children, the elderly, and immunocompromised
people have unequivocally been shown to be very safe.
Recombinant interferon has also been shown to be highly
effective and safe for the treatment of hepatitis C. Recom-
binant peptides are highly useful not only in therapeutics,
but also in nutrition as dietary supplements or in cosmet-
ics.
We are now immersed, almost without realizing it, in the
"recombinant era", in which we are able to prepare using
recombinant techniques, and free from viruses and pri-
ons, our own and most abundant protein, albumin,
which was previously obtained from human plasma [3].
If the plasma-derived products or human or animal tis-
sues are compared to recombinant products using phar-
macological efficacy criteria, no significant differences are
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found. However, when the criterion used is patient safety,
the situation is clearly different. For instance, recom-
binant products have not caused any serious or even mild
adverse events in their 17 years of clinical use for the treat-
ment of haemophilia (1990–2008), and even less adverse
events are to be expected with the new third-generation
recombinant products, that are completely free from
human or animal proteins [4,5]. By contrast, blood
plasma-derived products, since 1965, have caused thou-
sands of deaths in hemophilic patients worldwide due to
HIV and HCV infection, and will continue to cause deaths
because of the side effects of anti-HIV drugs, particularly
from cardiovascular and renal disease, and from cirrhosis
and hepatocarcinoma in the 60% of patients who do not
respond to current treatment for hepatitis C virus. No
patient has acquired any significant disease-causing path-
ogen from a plasma-derived commercial therapeutic since
1987 due to advances in plasma screening, purification
and pathogen inactivation technology. Also in the current
era of haemophilia care, the most significant complica-
tion remains inhibitor development. To this respect there
is a lot of controversy [6,7].
Although plasma-derived products of human origin are
highly safe as regards lipid envelope viruses such as HIV,
HCV, and HBV, they are not free from the well known
recently emerging risks resulting from the profound social
changes occurring in the world. Such risks include trans-
mission of new diseases, among which particular mention
should be made of prion diseases such as the variant
Creutzfeldt-Jakob disease (vCJD), or "mad cow disease"
[8], which is transmitted through blood [9]. There is also
a risk of transmission of the so-called emerging diseases
which cause epidemics or pandemics – by crossing the
"interspecies" barrier – in populations that were previ-
ously unaffected, or by other viruses that may be resistant
to viral inactivation processes [10]. At present a lot of
measures are been adopted in the selection of blood
donors, the use of blood (leucodepletion) and in the
plasma-derived products obtention.
There is therefore an almost universal consensus in rec-
ommending use of recombinant products. Thus, in
Europe, their use is recommended in the "European
Guidelines for Recombinant Therapies" [11], and several
specific countries, such as the United Kingdom [12], Aus-
tralia [13], or Spain [14], also advocate their use. Emerg-
ing pathogens in haemophilia have contributed to the
evolution and adoption of recombinant products (partic-
ularly the 3rd-generation products) [15].
The immediate question is: why are not recombinant
products more widely used, given their high efficacy and
maximum safety? It is difficult to answer this question if
we do not go beyond the Hippocratic Medicine we have
been taught [16]. It could be for conservative reasons,
derived from fear of the unknown, but reasons may also
be merely economic or related to "solidarity" in sharing
the cost of treatment. It should be remembered that
recombinant technology implies higher cost (80 percent
higher) from both the treatment itself and the investment
for pharmaceutical companies or public administrations
that try to implement healthcare policies with an equita-
ble sharing of budgets, though they may sometimes not
be in tune with some physicians or with patients them-
selves. Finally, we cannot rule out the existence of poten-
tial conflicts of interest regarding specific products from
certain companies in collusion with the physicians who
prescribe them.
In any case, clinical practice, which has always involved
certain risks, becomes more complicated now that safer
and more effective, but also more costly, products are
available. In this scenario, the clinician who manages and
tries to cure patients is faced with the dilemma of prescrib-
ing, sometimes within a very limited range of choices, the
Table 1: Some recombinant proteins used in clinical treatment
Protein Clinical utility
Coagulant factors Haemophilia A and B
DNase I Cystic fibrosis
Erythropoietin Anaemia in chronic renal disease
Glucocerebrosidase Gaucher disease
Growth hormone Nanism hypophyseal
Insulin Diabetes
Alpha interferon Some leukaemias, Kaposi's sarcoma, hepatitis B and C
Gamma-1b interferon Chronic granulomatous disease
Interleukin-2, -3 and -4 Immunotherapy of cancer
Tissue-type plasminogen activator Acute myocardial infarction, massive pulmonary embolism
Antibodies for cellular immunotherapy Neoplasic processes
Vaccines Influenza, hepatitis A and B
Monoclonal antibodies anti-antibodies Lupus, rheumatoid arthritisPublish with BioMed Central    and   every 
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safest and most effective pharmacological product with
the best safety/efficacy/cost ratio.
In short, we are faced with the interesting but also unfor-
tunate paradox of pharmacology – avoidable for some,
unsolvable for others – that a greater progress in therapeu-
tic procedures is not always associated with a greater
implementation of those safer resources for the simple
reason that they are more expensive. Are we forgetting that
patient safety should take precedence over cost or any
other underlying reason?
References
1. Watson JD, Crick FHC: A structure for deoxyribose nucleic
acid.  Nature 1953, 171:737-738.
2. Gibney J, Johannsson G: Safety of growth hormone replace-
ment therapy in adults.  Expert Opin Drug Saf 2004, 3:305-316.
3. Bosse D, Praus M, Kiessling P, Nyman L, Andresen C, Waters J, Schin-
del F: Phase I comparability of recombinant human albumin
and human serum albumin.  J Clin Pharmacol 2005, 45:57-67.
4. Manno CS: The promise of third-generation recombinant
therapy and gene therapy.  Semin Hematol 2003, 40(3 Suppl
3):23-28.
5. Ananyeva N, Khrenov A, Darr F, Summers R, Sarafanov A, Saenko E:
Treating haemophilia A with recombinant blood factors: A
comparison.  Expert Opin Pharmacother 2004, 5:1061-1070.
6. Chalmers EA, Brown SA, Keeling D, Liesner R, Richards M, Stirling D,
Thomas A, Vidler V, Williams MD, Young D, (Paediatric Working
Party of UKHCDO): Early factor VIII exposure and subsequent
inhibitor development in children with severe haemophilia
A.  Haemophilia 2007, 13:149-155.
7. AHCDC (Association of Haemophilia Clinic Directors of Canada): A
prospective surveillance study of factor VIII inhibitor devel-
opment in the Canadian haemophilia A population following
the switch to a recombinant factor VIII product formulated
with sucrose.  Haemophilia 2008, 14:281-286.
8. Ironside JW, Head MW: Neuropathology and molecular biology
of variant Creutzfeldt-Jakob disease.  Curr Top Microbiol Immunol
2004, 284:133-159.
9. Ludlam CA, Turner ML: Managing the risk of transmission of
variant Creutzfeldt Jakob disease by blood products.  Br J Hae-
matol 2006, 132:13-24.
10. Ungchusak K, Auewarakul P, Dowell SF, Kitphati R, Auwanit W,
Puthavathana P, Uiprasertkul M, Boonnak K, Pittayawonganon C, Cox
NJ, Zaki SR, Thawatsupha P, Chittaganpitch M, Khontong R, Simmer-
man JM, Chunsutthiwat S: Probable person-to-person transmis-
sion of avian influenza A virus (H5N1).  N Engl J Med 2005,
352:333-340.
11. Celis P, Silvester G: European regulatory guidance on virus
safety of recombinant proteins, monoclonal antibodies and
plasma derived medicinal products.  Dev Biol 2004, 118:3-10.
12. UKHCDO (United Kingdom Haemophilia Centre Doctors' Organisa-
tion):  Guidelines on the selection and use of therapeutic
products to treat haemophilia and other hereditary bleeding
disorders.  Haemophilia 2003, 9:1-23.
13. AFH (Australian Foundation of Haemophilia): Update on access to
recombinant factor VIII and recombinant factor IX for the
treatment of haemophilia in Australia.   [http://www.haemo
philia.org.au/news/id/11].
14. SCRFVE (Scientific Committee of the Royal Foundation"Victory
Eugenia"): Guidelines 2006 on the selection and use of thera-
peutic products to treat haemophilia and other hereditary
bleeding disorders, in Spain.   [http://www.hemofilia.com//fotos/
964dtmy8f7w.pdf].
15. Pipe S: Consideration in haemophilia therapy selection.  Semin
Hematol 2006, 43(2 Suppl 3):S23-7.
16. Liras A: On patients' rights. From Hippocratic Medicine to
our Third Millennium.  J Spanish Federation of Haemophilia 2001,
26:41-44.